Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0072u-cyp2d6-2d7-hybrid-targeted-sequence-analysis
    Ask Trek AI about this page

    CPT 0072U: CYP2D6–2D7 Hybrid Gene Targeted Sequence Analysis

    CPT code 0072U is a Proprietary Laboratory Analyses (PLA) test for the CYP2D6–2D7 Hybrid Gene Targeted Sequence Analysis developed by the Mayo Clinic Laboratory used as a follow-up genetic sequencing assay when the initial 0070U test does not resolve a patient’s CYP2D6 genotype; the service type is molecular diagnostic / targeted gene sequencing, typically performed in an clinical molecular diagnostics laboratory (specialty reference lab) as an outpatient or send-out specimen.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0072U policy alerts

    Get alerted when payer policies referencing 0072U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A patient is referred for targeted genetic analysis after an initial pharmacogenomic assay yields an inconclusive CYP2D6 result. The patient is typically an adult or pediatric patient taking or being considered for medications metabolized by CYP2D6 (for example, certain antidepressants, opioids, beta-blockers, or tamoxifen) where genotype-directed prescribing may affect safety or efficacy. A clinician (often a clinical pharmacologist, psychiatrist, oncologist, pain specialist, or primary care provider) orders the follow‑up test 0072U to resolve a suspected CYP2D6–2D7 hybrid allele that interfered with the initial genotype call.

    Workflow:

    • The ordering clinician documents indication and relevant medications in the chart and sends a specimen (usually blood or saliva) to the performing laboratory.

    • The laboratory receives the specimen, verifies patient identifiers, and performs targeted sequence analysis using the proprietary Mayo Clinic Laboratory method specifically described by 0072U to detect CYP2D6–2D7 hybrid alleles.

    • The laboratory interprets results and issues a report that clarifies the CYP2D6 genotype/allele status, including presence or absence of hybrid alleles and predicted metabolizer phenotype.

    • The ordering clinician reviews the report and incorporates the clarified genotype into medication selection or dosing decisions and documents the pharmacogenomic result in the EHR with problem list or medication reconciliation notes.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0070UCYP2D6 Gene Targeted Sequence Analysis (initial assay)Initial pharmacogenomic assay; 0072U is a follow‑up when 0070U is inconclusive for CYP2D6 genotype due to possible hybrid alleles.

    81225 | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) gene analysis, common variants (eg, *2, *3, *4, *5, *6), single or multiple variants; genotyping by targeted sequence analysis | Commonly used CYP2D6 genotyping code for targeted variant panels; may be used before or instead of PLA codes depending on laboratory methods.

    81479 | Unlisted molecular pathology procedure | Used in workflows when a specific PLA code is not available, or for custom molecular testing adjuncts to targeted sequence analysis.

    88360 | Immunohistochemistry or special stains interpreted by a pathologist (qualitative or semiquantitative) | Not directly related but appears in some molecular pathology workflows when tissue-based ancillary studies are required.

    G0452 | Pharmacogenetic testing, multiple gene analysis (list separately in addition to primary test) | Applicable in broader pharmacogenomic panels where CYP2D6 testing is part of multi-gene reports.

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    82Modifier 82 is appended to a surgical CPT code to indicate that an attending physician acted as an assistant because a qualified resident surgeon was unavailable. In teaching hospitals it documents…- When to use: Append modifier 82 in teaching-hospital settings to indicate a physician served as an assistant surgeon because a qualified resident surgeon was unavailable (includes situations where…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    2080P0206X
    207RH0000X
    207L00000X
    208D00000X
    207Q00000X
    2083A0100X
    156FC0800X
    207RC0000X

    Related ICD-10-CM Codes

    25 rows

    ICD-10-CM CodeDescription
    E03.9Hypothyroidism, unspecified
    E66.01Morbid (severe) obesity due to excess calories
    E66.9Obesity, unspecified
    E78.5Hyperlipidemia, unspecified
    F10.20Alcohol dependence, uncomplicated
    F19.10Other psychoactive substance abuse, uncomplicated
    F32.9Major depressive disorder, single episode, unspecified
    F33.1Major depressive disorder, recurrent, moderate
    G47.00Insomnia, unspecified
    G47.33Obstructive sleep apnea (adult) (pediatric)

    Showing 1–10 of 25

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.